234 related articles for article (PubMed ID: 38203310)
1. Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients.
Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
[TBL] [Abstract][Full Text] [Related]
2. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
4. The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis.
Ye L; Cai L; Fu Y; Zhuang D; Hu X; Jie Y
World J Surg Oncol; 2021 Jan; 19(1):12. PubMed ID: 33441137
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
6. Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?
Marques IS; Tavares V; Neto BV; Mota INR; Pereira D; Medeiros R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569483
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour.
Tavares V; Pinto R; Assis J; Pereira D; Medeiros R
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188331. PubMed ID: 31689458
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
9. The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling
Dai T; Liang J; Liu W; Zou Y; Niu F; Li M; Zhang H; Li C; Fan M; Cui G
Bioengineered; 2021 Dec; 12(2):10771-10781. PubMed ID: 34793263
[TBL] [Abstract][Full Text] [Related]
10. Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in Ovarian Cancer.
Wang J; Zhang X; Zheng F; Yang Q; Bi F
J Ovarian Res; 2023 Aug; 16(1):177. PubMed ID: 37633972
[TBL] [Abstract][Full Text] [Related]
11. Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients.
Tavares V; Pinto R; Assis J; Coelho S; Brandão M; Alves S; Pereira D; Medeiros R
Pharmacogenomics J; 2021 Apr; 21(2):222-232. PubMed ID: 33161412
[TBL] [Abstract][Full Text] [Related]
12. The Combination of D-dimer and Glasgow Prognostic Score Can Be Useful in Predicting VTE in Patients with Stage IIIC and IVA Ovarian Cancer.
Kubo K; Nakamura K; Okamoto K; Matsuoka H; Ida N; Haruma T; Ogawa C; Masuyama H
Acta Med Okayama; 2022 Apr; 76(2):129-135. PubMed ID: 35503440
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression.
Jiang R; Zhang H; Zhou J; Wang J; Xu Y; Zhang H; Gu Y; Fu F; Shen Y; Zhang G; Feng L; Zhang X; Chen Y; Shen F
Cell Death Dis; 2021 Feb; 12(2):145. PubMed ID: 33542185
[TBL] [Abstract][Full Text] [Related]
14. Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
Fu LL; Li CJ; Xu Y; Li LY; Zhou X; Li DD; Chen SX; Wang FG; Zhang XY; Zheng LW
Crit Rev Eukaryot Gene Expr; 2017; 27(2):183-195. PubMed ID: 28845767
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a mouse model for ovarian cancer-associated venous thromboembolism.
Ma S; Yin S; Zheng Y; Zang R
Exp Biol Med (Maywood); 2023 Jan; 248(1):26-35. PubMed ID: 36036485
[TBL] [Abstract][Full Text] [Related]
16. HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer.
Chai Y; Liu J; Zhang Z; Liu L
Cancer Med; 2016 Jul; 5(7):1588-98. PubMed ID: 27075229
[TBL] [Abstract][Full Text] [Related]
17. LncRNAs and MiRNAs: New Targets for Resveratrol in Ovarian Cancer Research.
Chaichian S; Bidgoli SA; Nikfar B; Moazzami B
Curr Med Chem; 2023; 30(28):3238-3248. PubMed ID: 36372916
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA XIST is down-regulated and correlated to better prognosis in ovarian cancer.
Hu Y; Mei XQ; Tang D
Math Biosci Eng; 2020 Jan; 17(3):2070-2081. PubMed ID: 32233524
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
[TBL] [Abstract][Full Text] [Related]
20. The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC).
Malgundkar SH; Tamimi Y
Hum Genet; 2024 Feb; 143(2):107-124. PubMed ID: 38276976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
